Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs)-Reference-Cited by-同舟云学术

Discovery of Potent and Selective Receptor-Interacting Serine/Threonine Protein Kinase 2 (RIPK2) Inhibitors for the Treatment of Inflammatory Bowel Diseases (IBDs)

Published:2022-06-16 Issue:13 Volume:65 Page:9312-9327
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Yuan Xue¹,Chen Yong¹,Tang Minghai¹,Wei Yuhan¹,Shi Mingsong¹,Yang Yingxue¹,Zhou Yanting¹,Yang Tao¹,Liu Jiang¹,Liu Kongjun¹,Deng Dexin¹,Zhang Chufeng¹,Chen Lijuan¹²^ORCID

Affiliation:

1. Laboratory of Natural and Targeted Small Molecule Drugs, State Key Laboratory of Biotherapy and Cancer Center and Collaborative Innovation Center of Biotherapy, West China Hospital of Sichuan University, Chengdu 610041, China

2. Chengdu Zenitar Biomedical Technology Co., Ltd., Chengdu 610041, China

Funder

China Postdoctoral Science Foundation

West China Hospital, Sichuan University

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c00604

Reference34 articles.

1. The burden of inflammatory bowel disease in Europe